These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36086937)

  • 1. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
    Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N
    Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
    Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
    Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
    Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.
    Martinez S; Sindu D; Nailor MD; Cherrier L; Tokman S; Walia R; Goodlet KJ
    Transpl Infect Dis; 2024 Jun; 26(3):e14279. PubMed ID: 38742601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
    JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
    J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis.
    Moore WJ; Boutin CA; Tanna S
    Curr Opin Infect Dis; 2023 Dec; 36(6):514-521. PubMed ID: 37773928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis.
    Kuhn A; Puttkammer J; Madigan T; Dinnes L; Khan S; Ferdjallah A; Kohorst M
    Transplant Cell Ther; 2023 Jan; 29(1):62.e1-62.e4. PubMed ID: 36244677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
    Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
    Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
    Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences.
    Hirama T; Shundo Y; Watanabe T; Ohsumi A; Watanabe T; Okada Y
    Clin Exp Med; 2024 Apr; 24(1):68. PubMed ID: 38578337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
    Hinman B; Cox J; Umoru G; Kamble R; Musick W
    Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches.
    Trappe M; Affeldt P; Grundmann F; Kann M; Koehler FC; Müller RU; Stippel D; Kaiser R; Knops E; Heger E; Steger G; Klein F; Kurschat C; Di Cristanziano V
    Transpl Infect Dis; 2024 Feb; 26(1):e14233. PubMed ID: 38180168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.